247 related articles for article (PubMed ID: 22212142)
41. [Malignant lymphoma of the skin].
Burg G; Dommann S; Dummer R
Ther Umsch; 1993 Dec; 50(12):828-34. PubMed ID: 8171405
[TBL] [Abstract][Full Text] [Related]
42. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop.
Swerdlow SH; Quintanilla-Martinez L; Willemze R; Kinney MC
Am J Clin Pathol; 2013 Apr; 139(4):515-35. PubMed ID: 23525619
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates.
Morales AV; Arber DA; Seo K; Kohler S; Kim YH; Sundram UN
Am J Dermatopathol; 2008 Oct; 30(5):425-30. PubMed ID: 18806482
[TBL] [Abstract][Full Text] [Related]
45. Regression of cutaneous intravascular lymphoma with rituximab.
Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
[TBL] [Abstract][Full Text] [Related]
46. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
Senff NJ; Noordijk EM; Kim YH; Bagot M; Berti E; Cerroni L; Dummer R; Duvic M; Hoppe RT; Pimpinelli N; Rosen ST; Vermeer MH; Whittaker S; Willemze R; ;
Blood; 2008 Sep; 112(5):1600-9. PubMed ID: 18567836
[TBL] [Abstract][Full Text] [Related]
47. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Grange F; Beylot-Barry M; Courville P; Maubec E; Bagot M; Vergier B; Souteyrand P; Machet L; Dalac S; Esteve E; Templier I; Delaporte E; Avril MF; Robert C; Dalle S; Laroche L; Delaunay M; Joly P; Wechsler J; Petrella T
Arch Dermatol; 2007 Sep; 143(9):1144-50. PubMed ID: 17875875
[TBL] [Abstract][Full Text] [Related]
48. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts.
Kempf W; Kazakov DV; Belousova IE; Mitteldorf C; Kerl K
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1696-709. PubMed ID: 25715748
[TBL] [Abstract][Full Text] [Related]
49. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
50. New aspects in the biology of cutaneous B-cell lymphomas.
Pimpinelli N
J Cutan Pathol; 2006 Feb; 33 Suppl 1():6-9. PubMed ID: 16412207
[TBL] [Abstract][Full Text] [Related]
51. Somatostatin receptor scintigraphy in primary cutaneous T- and B-cell lymphomas.
Valencak J; Trautinger F; Raderer M; Chott A; Der-Petrossian M; Ivancic-Brandenberger E; Knobler R; Kurtaran A; Hoffmann M
J Eur Acad Dermatol Venereol; 2010 Jan; 24(1):13-7. PubMed ID: 19515078
[TBL] [Abstract][Full Text] [Related]
52. [Prognosis of primary cutaneous lymphomas].
Grange F; Bagot M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
[TBL] [Abstract][Full Text] [Related]
53. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
54. Cutaneous B-cell lymphoma treated with rituximab infusions.
Schneider LA
Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
[No Abstract] [Full Text] [Related]
55. Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2013 Jan; 88(1):73-6. PubMed ID: 23379008
[TBL] [Abstract][Full Text] [Related]
56. [Cutaneous lymphoma].
Beyeler M; Burg G; Dummer R
Hautarzt; 2004 Oct; 55(10):1005-16; quiz 1017. PubMed ID: 15349694
[TBL] [Abstract][Full Text] [Related]
57. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers.
Senff NJ; Hoefnagel JJ; Jansen PM; Vermeer MH; van Baarlen J; Blokx WA; Canninga-van Dijk MR; Geerts ML; Hebeda KM; Kluin PM; Lam KH; Meijer CJ; Willemze R
J Clin Oncol; 2007 Apr; 25(12):1581-7. PubMed ID: 17353548
[TBL] [Abstract][Full Text] [Related]
58. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
59. Primary cutaneous marginal zone B-cell lymphoma: clinical and histological aspects.
Khaled A; Sassi S; Fazaa B; Ben Hassouna J; Ben Romdhane K; Kamoun MR
Pathologica; 2009 Feb; 101(1):18-20. PubMed ID: 19771768
[TBL] [Abstract][Full Text] [Related]
60. The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases.
Plaza JA; Kacerovska D; Stockman DL; Buonaccorsi JN; Baillargeon P; Suster S; Kazakov DV
Am J Dermatopathol; 2011 Oct; 33(7):649-55; quiz 656-8. PubMed ID: 21937906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
